Table 1:
Demographic and clinical characteristics of children enrolled in the study
| Non-Eosinophilic esophagitis controls (N=38) | Eosinophilic esophagitis (N=42) | p value | |
|---|---|---|---|
| Age (years) [Mean ± SD] | 11 ± 4 | 11 ± 4 | 1.00 |
| Males, [Number (%)] | 10 (26) | 34 (81) | < 0.001 |
| Ethnicity, [Number (%)] | |||
| Caucasian | 36 (95) | 31 (74) | 0.01 |
| African American | 1 (3) | 11 (26) | 0.004 |
| Hispanic | 1 (3) | -- | 0.51 |
| Presenting symptoms, [Number (%)] | |||
| Reflux | 3 (8) | 13 (13) | 0.01 |
| Nausea | 7 (18) | 5 (12) | 0.06 |
| Dysphagia | -- | 19 (45) | 0.004 |
| Abdominal pain | 29 (76) | 21 (50) | 0.01 |
| Vomiting | 11 (29) | 20 (48) | 0.08 |
| Constipation | 18 (47) | 10 (24) | 0.03 |
| Diarrhea | 11 (4) | 10 (4) | 0.88 |
| Known eosinophilic esophagitis | -- | 39 (93) | < 0.001 |
| Duration of gastrointestinal complaints or eosinophilic esophagitis, [Number (%)] | |||
| ≤ 6 months | 10 (26) | 9 (22) | 0.67 |
| 7 – 12 months | 6 (16) | 7 (17) | 0.90 |
| 13 – 18 months | 3 (8) | 4 (10) | 0.75 |
| 19 – 24 months | 1 (3) | 4 (10) | 0.02 |
| > 24 months | 18 (47) | 17 (42) | 0.65 |
| Allergic comorbidities, [Number (%)] | |||
| Food allergies | 6 (16) | 36 (86) | < 0.001 |
| Asthma | -- | 15 (38) | 0.01 |
| Eczema | 5 (2) | 19 (8) | 0.05 |
| Allergic rhinitis | 8 (3) | 67 (28) | < 0.001 |
| Median (IQR) peak eosinophils per high power field (eos/hpf) | |||
| -- | 59 (0–105) | ||
| Eosinophilic esophagitis activity status, [Number (%)] | |||
| Active (≥ 15 eos/hpf) | 33 (79) | ||
| Inactive (< 15 eos/hpf) | 9 (21) | ||
| Ongoing Treatment, [Number (%)] | |||
| Proton pump | -- | 37 (88) | < 0.001 |
| inhibitors | |||
| Topical steroids | -- | 31 (74) | < 0.001 |
| Dietary elimination | -- | 30 (71) | < 0.001 |
SD: Standard deviation; IQR: Interquartile range